Kyle Kazan

Co-founder, Chairman, and CEO –

Glass House Group

Kazan began his career in law enforcement where he garnered his expertise in gang and drug identification / eradication. Soon thereafter, he was an advocate to end the war on drugs as a speaker for Law Enforcement Against Prohibition (LEAP). In 1991, Kazan began investing in distressed real estate and launched a total of 23 Private Equity funds.  The estimated value of properties currently owned and under management is more than $2 billion.  He served as a founding director for two opportunistic real estate funds, Grand River Properties and Dalton Berlin, which were based in Shanghai and Berlin, respectively.  Starting November of 2016, Kazan switched his focus to the regulated cannabis industry, and has since successfully closed four funds.  These funds consolidated into Glass House Group, which has assembled a portfolio of vertically-integrated assets.  Kazan holds a BA degree from the University of Southern California.


Farrar is a serial entrepreneur who began his career as part of the original team at Software.com, taking the company public in 1999.  Shortly thereafter, he served on the board of Seacology and was part of the founding team at Sonos, where he was involved with product design, development, sales, and customer support.  After Sonos, Farrar served as a board member for Heal the Ocean, was a founder and partner of ebook publishers iStoryTime Inc. and zuuka, and founded a Santa Barbara luxury rental company.  He ventured into the regulated cannabis industry by founding Elite Garden Wholesale, an agriculture technology company focused on developing products for the hydroponics industry.  Farrar currently sits on the Board of Directors of The Santa Barbara Bowl Foundation.

Graham Farrar

President and Board Director -

Glass House Group

Steve Ruchefsky

Board Director -

Glass House Group

Ruchefsky, a graduate of the The George Washington University Law School, practiced law in for 15 years specializing in the litigation of complex economic disputes.  Before leaving the practice of law, Ruchefsky was a partner at the New York City law firm, Morrison Cohen, a member of its management committee and chair of its specialized litigation group.  Since 2000, Ruchefsky has utilized his experience with complicated financial matters to become an active private investor, both as principal and as investment manager.  Through 2017, Mr. Ruchefsky served as the senior executive and private investment manager for the founder and Chief Executive Officer of a multibillion-dollar hedge fund and as such was responsible for the initial funding and development of many successful businesses and ventures.  Ruchefsky was responsible for the initial funding of Cougar Biotechnology Inc (CGRB: NASDAQ) paving the way for the development of the blockbuster oncology drug Zytiga (abiraterone acetate). Cougar was subsequently acquired by Johnson & Johnson in 2009 for $1 billion.  In addition, Ruchefsky was a lead early investor and founding director of Kite Pharma, Inc. (KITE:NASDAQ) which successfully developed the revolutionary oncology treatment commercially known as Yescarta. Kite was acquired by Gilead Sciences in 2017 for $11.9 billion.  Currently, Ruchefsky is Executive Chairman of MD Solar Sciences, Inc., and a Founder and board member of Regel Therapeutics and Script BioSciences.  Ruchefsky also serves as a Trustee of the Berklee College of Music.    


Rosenwald began her career as Teach For America Corps member in New York City.  In 2011, she became a founding teacher at KIPP Star Elementary School and quickly became a teacher leader.  She began real estate investment in 2013 with Beach Front Properties LLC and managed a $500M portfolio of opportunistic real estate investments.  In November of 2016, Rosenwald began supervising the operations of 4 funds in the regulated cannabis industry – these funds consolidated into Glass House Group.  Today, Rosenwald sits on the board of Glass House Group as a director.  She holds a BA degree from the University of Pennsylvania, MA in Education from Hunter College, and an MBA from UCLA Anderson School of Business.

Jocelyn Rosenwald

Co-founder and Board Director-

Glass House Group



Dr. Orrin Devinsky

Chief Medical Advisor -

Glass House Group

Orrin Devinsky is a Professor of Neurology, Neuroscience, Neurosurgery & Psychiatry at the NYU School of Medicine. He directs the NYU Epilepsy Center and Saint Barnabas Institute of Neurology. His epilepsy research includes cannabinoid therapies, genetic epilepsies and precision therapies, sudden death in epilepsy, autism, healthful behavioral changes, therapeutic electrical stimulation, quality-of-life, cognitive and behavioral issues, and surgical therapy. He was lead investigator for the Epidiolex Dravet and Lennox-Gastaut studies and has been involved in studies leading to FDA approval of many other medications. He founded Finding A Cure for Epilepsy and Seizures (FACES) and co-founded the Epilepsy Therapy Project and epilepsy.com.  He has been the recipient of numerous NIH, NSF, CDC and other organizations.  He is on the Scientific Advisory Boards for eight disease organizations. Other academic interests include evolutionary biology, nutrition, and behavioral neurology.